Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Waiting to discuss P1 on Oct 13 will not be a good sign

<< Previous

Bullboard Posts

Next >>

Comment by Joemareon Sep 30, 2022 12:37pm

144 Views

Post# 34997815

RE:RE:RE:RE:RE:RE:RE:Waiting to discuss P1 on Oct 13 will not be a good sign

If they recruited as per plan, they should have the followintg:
proof of concept
response data/cancer type and safety data (at least n=12).

Let's not minimiz proof of concept as they have to tell us that it's not the free docetaxel that is giving the response but the TH1902 combo is doing the job. Not an easy task to demonstrate without doubt...

Nothing much really. Just the fact that they have had leadership to get centres to recruit patients. Simple R&D.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market